Tech Company Financing Transactions
NewLimit Funding Round
NewLimit closed a $40 million Series A funding round on 5/16/2023. Backers included Dimension, Founders Fund and Kleiner Perkins Caufield & Byers.
Transaction Overview
Company Name
Announced On
5/16/2023
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to accelerate growth, both organically and externally, and expand operations.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
901 Gateway Blvd
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
NewLimit is a biotechnology company working to radically extend human healthspan. We're developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Co-Founder
Brian Armstrong
Co-Founder
Greg Johnson
Co-Founder
Jacob Kimmel
President
Michael Polansky
Browse more venture capital transactions:
Prev: 5/16/2023: Auradine venture capital transaction
Next: 5/16/2023: Rooms.xyz venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs